Meagan Parrish
Lead Editor at Industry Dive
Lead Editor at PharmaVOICE
Senior editor for @industrydive, follower of the pharma world, proud mama, frequent flyer, occasional belly dancer.
Articles
-
1 week ago |
pharmavoice.com | Meagan Parrish
This audio is auto-generated. Please let us know if you have feedback. What started as the shocking murder of a healthcare executive has now become a watershed moment for an entire industry. Brian Thompson, the CEO of UnitedHealthcare, was gunned down in December while walking along a Manhattan sidewalk. After an intense manhunt, the suspected assailant was caught and identified as Luigi Mangione. The case against 26-year-old Mangione, which includes state and federal charges, is moving swiftly.
-
1 week ago |
pharmavoice.com | Meagan Parrish
This audio is auto-generated. Please let us know if you have feedback. The U.S.’s billowing trade policies rattled global markets this week with the onset of new tariffs that were then mostly paused. Although the uncertainty took a bite out of Big Pharma stocks, the industry was mostly spared from the worst of the upheaval.
-
2 weeks ago |
pharmavoice.com | Meagan Parrish
This audio is auto-generated. Please let us know if you have feedback. After a few years of booming interest in AI platforms, the rubber has hit the road. Now, the market is watching closely to see if drugs discovered with the new tech will pan out in the clinic — and are still worth backing.
-
3 weeks ago |
pharmavoice.com | Meagan Parrish |Amy Baxter
This audio is auto-generated. Please let us know if you have feedback. A massive round of job cuts hit HHS this week, impacting a wide range of staffers of all rank and file. And more details about who exactly got the boot are starting to emerge. An entire team devoted to FDA communications was among the 3,500 agency employees who were fired on Tuesday, NPR reported.
FDA’s ‘mixed signals’ on diversity have entangled clinical trials. Here’s how pharma can push ahead.
3 weeks ago |
pharmavoice.com | Meagan Parrish
This audio is auto-generated. Please let us know if you have feedback. The word “diversity” has become a political hot potato in the U.S. as the Trump administration ramps up its assault on DEI-related policies. For pharma, the stark regulatory shift has collided with major business initiatives already set in motion. While many of the anti-DEI directives from the White House are aimed at hiring practices, the stakes go deeper for pharma, especially in the realm of clinical trials.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 295
- Tweets
- 110
- DMs Open
- No
Recently caught up with SIGA Technologies, one of the sole producers of a monkeypox treatment, to find out how they're preparing for the potential of an ongoing outbreak. Here's my report: https://t.co/jFudmaQuQh
There are a host of reasons pharma could get its M&A groove back in 2022. Here's a look at some of the leading market factors on the pharma M&A scene. https://t.co/KsO1vfnZlE
For one of my first PharmaVoice articles, I picked a really interesting company to write about. With a novel platform and innovative vaccines, @vaxxinity is worth having on your pharma radar. https://t.co/sUmGTUcFPp